Li Jing-Hua, Sun Shan-Shan, Li Ning, Lv Peng, Xie Shu-Yang, Wang Ping-Yu
Department of Epidemiology, Binzhou Medical University, YanTai, ShanDong 264003, P.R. China.
Key Laboratory of Tumor Molecular Biology in Binzhou Medical University, Department of Biochemistry and Molecular Biology, Binzhou Medical University, YanTai, ShanDong 264003, P.R. China.
Oncotarget. 2017 Aug 14;8(54):91938-91949. doi: 10.18632/oncotarget.20262. eCollection 2017 Nov 3.
MicroRNA-205 (miR-205) was revealed as a novel diagnostic and prognostic biomarker for lung cancer, but the results in the published papers were inconsistent. This meta-analysis aimed to investigate the diagnostic and prognostic roles of miR-205 in patients with lung cancer. Totally, 16 eligible articles were included, among which 10 articles investigated the diagnostic value of miR-205, 5 articles examined its prognostic values, and 1 article studied both diagnostic and prognostic values. For the diagnostic meta-analysis, the pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and the overall area under the curve of miR-205 for patients with lung cancer were 0.88 (95% = 0.78 - 0.94), 0.78 (95% = 0.66 - 0.86), 4.00 (95% = 2.47 - 6.49), 0.16 (95% = 0.08 - 0.30), 25.86 (95% = 9.29 - 71.95), and 0.90 (95% = 0.87 - 0.92), respectively, indicating that miR-205 is a useful biomarker for diagnostic of lung cancer. The subgroup analysis further demonstrated that miR-205 had an excellent overall accuracy for detection with tissue samples compare with blood samples. For the prognostic meta-analysis, the pooled outcome of the disease-free survival and recurrence-free survival analyses revealed that increased miR-205 levels had a protective role in the prognosis of patients with lung cancer (pooled HR = 0.86, 95% CI: 0.78-0.96, z = 2.83, = 0.005). In conclusion, miR-205 may be a promising biomarker for detection, predicting the recurrence of patients with lung cancer.
微小RNA-205（miR-205）被揭示为肺癌一种新的诊断和预后生物标志物，但已发表论文中的结果并不一致。本荟萃分析旨在探讨miR-205在肺癌患者中的诊断和预后作用。总共纳入了16篇符合条件的文章，其中10篇文章研究了miR-205的诊断价值，5篇文章研究了其预后价值，1篇文章同时研究了诊断和预后价值。对于诊断性荟萃分析，miR-205对肺癌患者的合并敏感性、特异性、阳性似然比、阴性似然比、诊断比值比以及曲线下总面积分别为0.88（95% = 0.78 - 0.94）、0.78（95% = 0.66 - 0.86）、4.00（95% = 2.47 - 6.49）、0.16（95% = 0.08 - 0.30）、25.86（95% = 9.29 - 71.95）和0.90（95% = 0.87 - 0.92），表明miR-205是肺癌诊断的有用生物标志物。亚组分析进一步表明，与血液样本相比，miR-205在组织样本检测中具有出色的总体准确性。对于预后性荟萃分析，无病生存和无复发生存分析的合并结果显示，miR-205水平升高对肺癌患者的预后具有保护作用（合并HR = 0.86，95%CI：0.78 - 0.96，z = 2.83， = 0.005）。总之，miR-205可能是检测肺癌、预测患者复发的有前景的生物标志物。
